ArticleJournal of experimental & clinical cancer research : CR2026
Selenite modulates phenotype-dependent epithelial-mesenchymal plasticity in pancreatic ductal adenocarcinoma: integrated in vitro analyses and patient-derived ex vivo tissue-slice cultures.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is characterized by profound therapy resistance, desmoplasia, and phenotypic plasticity. While sodium selenite is a redox-active compound with reported tumor-selective cytotoxicity, its impact on epithelial-mesenchymal transition (EMT) states in PDAC remains insufficiently defined. We investigated whether selenite modulates EMT-associated phenotypes in a dose- and context-dependent manner using complementary in vitro and patient-derived ex vivo models and linked marker shifts to histological tumor regression in PDAC tissue slices.
methodsThree PDAC cell lines spanning distinct baseline EMT states (PANC-1, HPAF-II, Capan-2) were profiled by quantitative immunofluorescence for a predefined epithelial (EpCAM, cytokeratin, E-cadherin) and mesenchymal-associated (AHNAK2, ITGAV, vimentin) protein panel, with or without TGF-β pretreatment. Ex vivo tissue slices from treatment-naïve, non-metastatic PDAC resections (n = 10) were cultured in a within-patient paired design (0 h, 24 h, 48 h controls; 5 or 15 µM selenite during the second 24 h). Histological tumor regression was scored by a blinded pancreatic pathologist (Evans; CAP), compartment-resolved marker expression was quantified by multiplex immunofluorescence, and paired RNA sequencing was performed in a subset of donors (n = 4).
resultsIn vitro, responses were phenotype-contingent: the epithelial-biased HPAF-II and Capan-2 lines showed partial epithelial reinforcement and a consistent reduction of mesenchymal markers (particularly ITGAV, vimentin), whereas the mesenchymal-biased PANC-1 exhibited limited modulation. TGF-β pretreatment attenuated epithelial-promoting effects while suppression of mesenchymal markers was retained in a cell line-dependent manner. In ex vivo slices, selenite induced a dose-dependent improvement in histological tumor regression and increased the tumor-compartment epithelial-mesenchymal ratio at 15 µM, driven mainly by epithelial-marker upregulation, while mesenchymal markers showed no uniform suppression. At 15 µM, transcriptomics revealed a compact treatment response characterized by downregulation of basement-membrane/ECM modules without broad reversal across EMT gene sets; EMT scoring indicated heterogeneous shifts at 5 µM and a more consistent epithelial-leaning shift at 15 µM in most donors.
conclusionsSelenite was associated with reinforcement of epithelial features mainly in malignant PDAC compartments in a baseline-state-, dose-, and context-dependent manner, with higher-dose phenotypic shifts occurring alongside stronger histological tumor response in clinically proximal models.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.